Cardiomyopathy, Hypertrophic Clinical Trials

5 recruiting

Cardiomyopathy, Hypertrophic Trials at a Glance

7 actively recruiting trials for cardiomyopathy, hypertrophic are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Cleveland, Rochester, and Beijing. Lead sponsors running cardiomyopathy, hypertrophic studies include China National Center for Cardiovascular Diseases, Columbia University, and Hospital do Coracao.

Browse cardiomyopathy, hypertrophic trials by phase

Treatments under study

About Cardiomyopathy, Hypertrophic Clinical Trials

Looking for clinical trials for Cardiomyopathy, Hypertrophic? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiomyopathy, Hypertrophic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiomyopathy, Hypertrophic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled107 locationsNCT06481891
Recruiting

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

Sudden Cardiac DeathArrhythmogenic Right Ventricular DysplasiaCardiomyopathy, Dilated+11 more
Hospital do Coracao600 enrolled27 locationsNCT06546137
Recruiting
Not Applicable

Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy

Cardiomyopathy, Hypertrophic
Technical University of Munich24 enrolled1 locationNCT07077005
Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Cardiac AmyloidosisCardiomyopathy, HypertrophicLumbar Spinal Stenosis+3 more
Columbia University1,663 enrolled6 locationsNCT06034405
Recruiting
Not Applicable

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy

Atrial FibrillationRadiofrequency AblationCardiomyopathy, Hypertrophic
China National Center for Cardiovascular Diseases66 enrolled1 locationNCT05610215
Recruiting
Not Applicable

Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy

Minimally Invasive SurgeryCardiomyopathy, Hypertrophic Obstructive
China National Center for Cardiovascular Diseases132 enrolled1 locationNCT06391788
Recruiting

The Chinese Hypertrophic Cardiomyopathy Study(CHCS)

Cardiomyopathy, Hypertrophic
China National Center for Cardiovascular Diseases3,000 enrolled1 locationNCT02696135